WallStSmart

Alcon AG (ALC)vsBionano Genomics Inc (BNGO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 36903% more annual revenue ($10.63B vs $28.74M). ALC leads profitability with a 7.7% profit margin vs -109.9%. ALC earns a higher WallStSmart Score of 49/100 (D+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

BNGO

Avoid

33

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 4/9Altman Z: -13.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-24.0%)

Margin of Safety

-24.0%

Fair Value

$64.04

Current Price

$66.81

$2.77 premium

UndervaluedFair: $64.04Overvalued

Intrinsic value data unavailable for BNGO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

BNGO1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

Return on EquityProfitability
3.7%3/10

ROE of 3.7% — below average capital efficiency

Profit MarginProfitability
7.7%3/10

7.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BNGO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.46M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-84.3%2/10

ROE of -84.3% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity.

Bull Case : BNGO

The strongest argument for BNGO centers on Price/Book.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, Return on Equity, Profit Margin. A P/E of 40.7x leaves little room for execution misses.

Bear Case : BNGO

The primary concerns for BNGO are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

ALC profiles as a value stock while BNGO is a turnaround play — different risk/reward profiles.

BNGO carries more volatility with a beta of 1.62 — expect wider price swings.

ALC is growing revenue faster at 9.4% — sustainability is the question.

ALC generates stronger free cash flow (274M), providing more financial flexibility.

Bottom Line

ALC scores higher overall (49/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Bionano Genomics Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Bionano Genomics, Inc. is a life science instrumentation company in the genome analysis space. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?